KORU Medical : Presentation Q3 2022

KORU Medical Systems

Q3 2022 Earnings Call

November 9, 2022

1

Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 regarding our expectations for future performance, including but not limited to our future revenue, gross margin, operating expenses, and cash flow. Forward-looking statements are neither historical facts nor assurances of future performance and based only on our current beliefs, expectations and assumptions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: impact of COVID-19 related to new SCIg patient starts, plasma supply, clinical trial activity, supply chain and labor availability; inflationary impacts; effects of war and other global conflict; introduction of competitive products; availability of insurance reimbursement; changes in U.S. Food and Drug Administration regulations; changes to health care policies; success of our research and development efforts; our ability to raise capital if or when needed; acceptance of and demand for new and existing products; expanded market acceptance of the FREEDOM Syringe Infusion System and any new product we introduce; our ability to obtain required governmental approvals; success in enforcing and obtaining patents; continued performance by principal suppliers; continued customer preference to work through distributors; continued service of key personnel and attracting and maintaining new personnel; and general economic and business conditions, as well as those risks and uncertainties included under the captions "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021 and our Quarterly Report on Form 10-Q for the quarter ended June 30, which are available on the SEC website atwww.sec.gov [sec.gov]and on our website atwww.korumedical.com/investors [korumedical.com]. Any forward-lookingstatement made by us is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-lookingstatement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Sales: All references to sale(s) within the presentation refer to net sale(s).

2

Table Of Contents

Q3 2022 Highlights

Financial Summary

2022 Guidance

Closing Comments

Q3 2022 Highlights

Linda Tharby

President and Chief Executive Officer

4

Q3 2022 Strong Performance on Key Milestones

Q3 2022 marked fourth consecutive quarter of double-digit growth

Expanded Novel Therapies to 14 total collaborations, including four new Phase II clinical drug trials, and one drug progressed to Phase III

Strong core business performance - U.S. growth outpaced a growing subcutaneous immunoglobulin market, and international growth of 46.8% YOY

Improved sequential gross margins to 55.7% and cleared Q2 backorder

Strengthened executive team with new Vice President of Medical

Affairs

Raised FY 2022 revenue guidance to $27.5 - $28.0 million

5